JP6256772B2 - ヒストンデメチラーゼ阻害剤 - Google Patents
ヒストンデメチラーゼ阻害剤 Download PDFInfo
- Publication number
- JP6256772B2 JP6256772B2 JP2015549728A JP2015549728A JP6256772B2 JP 6256772 B2 JP6256772 B2 JP 6256772B2 JP 2015549728 A JP2015549728 A JP 2015549728A JP 2015549728 A JP2015549728 A JP 2015549728A JP 6256772 B2 JP6256772 B2 JP 6256772B2
- Authority
- JP
- Japan
- Prior art keywords
- preparation
- compound
- fluoro
- nmr
- mhz
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- MDHZNBDRDJQKNA-UHFFFAOYSA-N CC(C)(C)OC(N1CC(CC[n](c(c2c3)ccc3F)nc2I)CCC1)=O Chemical compound CC(C)(C)OC(N1CC(CC[n](c(c2c3)ccc3F)nc2I)CCC1)=O MDHZNBDRDJQKNA-UHFFFAOYSA-N 0.000 description 1
- VWIMPFAZHUNPKK-UHFFFAOYSA-N CCC[n](c1c2CCC=C1F)nc2Nc(cncc1)c1C(O)=O Chemical compound CCC[n](c1c2CCC=C1F)nc2Nc(cncc1)c1C(O)=O VWIMPFAZHUNPKK-UHFFFAOYSA-N 0.000 description 1
- JITWKGJFUDNUKH-UHFFFAOYSA-N CN1CCC(CC[n](c(cc2)c3cc2F)nc3Nc(cncc2)c2C(O)=O)CC1 Chemical compound CN1CCC(CC[n](c(cc2)c3cc2F)nc3Nc(cncc2)c2C(O)=O)CC1 JITWKGJFUDNUKH-UHFFFAOYSA-N 0.000 description 1
- QWHULRZVRSTPNH-UHFFFAOYSA-N CNCCCCC[n](c(cc1)c2cc1F)nc2Nc(cncc1)c1C(O)=O Chemical compound CNCCCCC[n](c(cc1)c2cc1F)nc2Nc(cncc1)c1C(O)=O QWHULRZVRSTPNH-UHFFFAOYSA-N 0.000 description 1
- NMKOEUOMKQUPGP-UHFFFAOYSA-N Fc(cc1)cc2c1[n](CC1OCCC1)nc2I Chemical compound Fc(cc1)cc2c1[n](CC1OCCC1)nc2I NMKOEUOMKQUPGP-UHFFFAOYSA-N 0.000 description 1
- GRCMLULLNYVGSI-UHFFFAOYSA-N Fc(ccc1n[n]2CC3OCCC3)cc1c2I Chemical compound Fc(ccc1n[n]2CC3OCCC3)cc1c2I GRCMLULLNYVGSI-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
- Enzymes And Modification Thereof (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261739521P | 2012-12-19 | 2012-12-19 | |
| US61/739,521 | 2012-12-19 | ||
| US201361792930P | 2013-03-15 | 2013-03-15 | |
| US61/792,930 | 2013-03-15 | ||
| PCT/US2013/076666 WO2014100463A1 (en) | 2012-12-19 | 2013-12-19 | Histone demethylase inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016503799A JP2016503799A (ja) | 2016-02-08 |
| JP2016503799A5 JP2016503799A5 (enExample) | 2016-12-01 |
| JP6256772B2 true JP6256772B2 (ja) | 2018-01-10 |
Family
ID=50931614
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015549728A Expired - Fee Related JP6256772B2 (ja) | 2012-12-19 | 2013-12-19 | ヒストンデメチラーゼ阻害剤 |
Country Status (17)
| Country | Link |
|---|---|
| US (4) | US9617242B2 (enExample) |
| EP (1) | EP2934145B1 (enExample) |
| JP (1) | JP6256772B2 (enExample) |
| AU (1) | AU2013361255B2 (enExample) |
| CA (1) | CA2895355A1 (enExample) |
| CY (1) | CY1119901T1 (enExample) |
| DK (1) | DK2934145T3 (enExample) |
| ES (1) | ES2658597T3 (enExample) |
| HR (1) | HRP20180067T1 (enExample) |
| HU (1) | HUE037312T2 (enExample) |
| LT (1) | LT2934145T (enExample) |
| PL (1) | PL2934145T3 (enExample) |
| PT (1) | PT2934145T (enExample) |
| RS (1) | RS56821B1 (enExample) |
| SI (1) | SI2934145T1 (enExample) |
| SM (1) | SMT201800070T1 (enExample) |
| WO (1) | WO2014100463A1 (enExample) |
Families Citing this family (69)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3139033A1 (en) | 2012-08-22 | 2014-02-27 | Cornell University | Methods for inhibiting fascin |
| ES2654143T3 (es) | 2012-10-02 | 2018-02-12 | Gilead Sciences, Inc. | Inhibidores de desmetilasas de histonas |
| SI2934145T1 (en) | 2012-12-19 | 2018-03-30 | Celgene Quanticel Research, Inc. | Histone demethylase inhibitors |
| CA2895808A1 (en) | 2012-12-21 | 2014-06-26 | Quanticel Pharmaceuticals, Inc. | Histone demethylase inhibitors |
| SG10201707027SA (en) | 2013-02-27 | 2017-09-28 | Epitherapeutics Aps | Inhibitors of histone demethylases |
| JP6320506B2 (ja) | 2013-03-12 | 2018-05-09 | セルジーン クオンティセル リサーチ，インク． | ヒストンデメチラーゼ阻害剤 |
| RU2015143517A (ru) | 2013-03-13 | 2017-04-19 | Дженентек, Инк. | Пиразолсодержащие соединения и их применения |
| WO2015127125A1 (en) | 2014-02-20 | 2015-08-27 | Cornell University | Compounds and methods for inhibiting fascin |
| CN106660982B (zh) * | 2014-06-25 | 2020-09-08 | 赛尔基因昆蒂赛尔研究公司 | 组蛋白脱甲基酶抑制剂 |
| JP2017526675A (ja) | 2014-08-27 | 2017-09-14 | ギリアード サイエンシーズ， インコーポレイテッド | ヒストンデメチラーゼを阻害するための化合物および方法 |
| SG11201702119PA (en) | 2014-09-17 | 2017-04-27 | Quanticel Pharmaceuticals Inc | Histone demethylase inhibitors |
| US10030017B2 (en) | 2014-09-17 | 2018-07-24 | Celgene Quanticel Research, Inc. | Histone demethylase inhibitors |
| SG11201702147TA (en) | 2014-09-17 | 2017-04-27 | Celgene Quanticel Res Inc | Histone demethylase inhibitors |
| EP3397617A4 (en) | 2015-12-28 | 2019-05-22 | Celgene Quanticel Research, Inc. | HISTONDEMETHYLASEINHIBITOREN |
| CN105601555B (zh) * | 2016-03-14 | 2018-07-31 | 苏州大学 | 一种制备硝基吲哚衍生物的方法 |
| WO2017161012A1 (en) * | 2016-03-15 | 2017-09-21 | Celgene Quanticel Research, Inc. | Histone demethylase inhibitors |
| US10150754B2 (en) | 2016-04-19 | 2018-12-11 | Celgene Quanticel Research, Inc. | Histone demethylase inhibitors |
| ES2969239T3 (es) | 2016-05-27 | 2024-05-17 | Gilead Sciences Inc | Combinación de ledipasvir y sofosbuvir para su uso en el tratamiento de infecciones por el virus de la hepatitis B en humanos |
| BR102017010009A2 (pt) | 2016-05-27 | 2017-12-12 | Gilead Sciences, Inc. | Compounds for the treatment of hepatitis b virus infection |
| JOP20190024A1 (ar) | 2016-08-26 | 2019-02-19 | Gilead Sciences Inc | مركبات بيروليزين بها استبدال واستخداماتها |
| SI3507276T1 (sl) | 2016-09-02 | 2022-01-31 | Gilead Sciences, Inc. | Spojine modulatorja toličnih receptorjev |
| WO2018045150A1 (en) | 2016-09-02 | 2018-03-08 | Gilead Sciences, Inc. | 4,6-diamino-pyrido[3,2-d]pyrimidine derivaties as toll like receptor modulators |
| KR20230010826A (ko) | 2016-10-14 | 2023-01-19 | 프리시젼 바이오사이언시스 인코포레이티드 | B형 간염 바이러스 게놈 내의 인식 서열에 대해 특이적인 조작된 메가뉴클레아제 |
| EP3535242B1 (en) * | 2016-10-20 | 2024-01-24 | B.G. Negev Technologies and Applications Ltd., at Ben-Gurion University | Dna primase and gyrase inhibitors |
| TWI714820B (zh) | 2017-01-31 | 2021-01-01 | 美商基利科學股份有限公司 | 替諾福韋艾拉酚胺(tenofovir alafenamide)之晶型 |
| UY37581A (es) | 2017-02-02 | 2018-08-31 | Gilead Sciences Inc | Compuestos para el tratamiento de la infección por virus de la hepatitis b |
| WO2018149986A1 (en) * | 2017-02-16 | 2018-08-23 | Oryzon Genomics, S.A. | 2-(bicyclo-heteroaryl)-isonicotinic derivatives as histone demethylase inhibitors |
| ES2991090T3 (es) | 2017-03-30 | 2024-12-02 | Univ Freiburg Albert Ludwigs | Inhibidores de KDM4 |
| BR102018007822A2 (pt) | 2017-04-20 | 2018-11-06 | Gilead Sciences, Inc. | composto, métodos para inibir pd-1, pd-l1 e/ou interação de pd-1/pd-l1 e para tratamento de câncer, composição farmacêutica, e, kit para tratamento de ou prevenção de câncer ou uma doença ou condição |
| JP7037667B2 (ja) | 2017-12-20 | 2022-03-16 | インスティチュート オブ オーガニック ケミストリー アンド バイオケミストリー エーエスシーアール，ヴイ．ヴイ．アイ． | Ｓｔｉｎｇアダプタータンパク質を活性化するホスホン酸結合を有する３’３’環状ジヌクレオチド |
| US11203610B2 (en) | 2017-12-20 | 2021-12-21 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 2′3′ cyclic dinucleotides with phosphonate bond activating the sting adaptor protein |
| WO2019160882A1 (en) | 2018-02-13 | 2019-08-22 | Gilead Sciences, Inc. | Pd-1/pd-l1 inhibitors |
| JP7050165B2 (ja) | 2018-02-26 | 2022-04-07 | ギリアード サイエンシーズ， インコーポレイテッド | Ｈｂｖ複製阻害剤としての置換ピロリジン化合物 |
| WO2019195181A1 (en) | 2018-04-05 | 2019-10-10 | Gilead Sciences, Inc. | Antibodies and fragments thereof that bind hepatitis b virus protein x |
| TWI833744B (zh) | 2018-04-06 | 2024-03-01 | 捷克科學院有機化學與生物化學研究所 | 3'3'-環二核苷酸 |
| TW202005654A (zh) | 2018-04-06 | 2020-02-01 | 捷克科學院有機化學與生物化學研究所 | ２，２，─環二核苷酸 |
| TWI818007B (zh) | 2018-04-06 | 2023-10-11 | 捷克科學院有機化學與生物化學研究所 | 2'3'-環二核苷酸 |
| US11142750B2 (en) | 2018-04-12 | 2021-10-12 | Precision Biosciences, Inc. | Optimized engineered meganucleases having specificity for a recognition sequence in the Hepatitis B virus genome |
| KR102591947B1 (ko) | 2018-04-19 | 2023-10-25 | 길리애드 사이언시즈, 인코포레이티드 | Pd-1/pd-l1 억제제 |
| WO2019211799A1 (en) | 2018-05-03 | 2019-11-07 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 2'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide |
| PE20210642A1 (es) | 2018-07-13 | 2021-03-23 | Gilead Sciences Inc | Inhibidores de pd-1/pd-l1 |
| WO2020028097A1 (en) | 2018-08-01 | 2020-02-06 | Gilead Sciences, Inc. | Solid forms of (r)-11-(methoxymethyl)-12-(3-methoxypropoxy)-3,3-dimethyl-8-0x0-2,3,8,13b-tetrahydro-1h-pyrido[2,1-a]pyrrolo[1,2-c] phthalazine-7-c arboxylic acid |
| US11236085B2 (en) | 2018-10-24 | 2022-02-01 | Gilead Sciences, Inc. | PD-1/PD-L1 inhibitors |
| EP4371987B9 (en) | 2018-10-31 | 2025-11-26 | Gilead Sciences, Inc. | Substituted 6-azabenzimidazole compounds as hpk1 inhibitors |
| EP3873608A1 (en) | 2018-10-31 | 2021-09-08 | Gilead Sciences, Inc. | Substituted 6-azabenzimidazole compounds having hpk1 inhibitory activity |
| WO2020178768A1 (en) | 2019-03-07 | 2020-09-10 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator |
| CN113574063B (zh) | 2019-03-07 | 2025-03-18 | 捷克共和国有机化学与生物化学研究所 | 3’3’-环二核苷酸及其前药 |
| WO2020178769A1 (en) | 2019-03-07 | 2020-09-10 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 2'3'-cyclic dinucleotides and prodrugs thereof |
| TWI751517B (zh) | 2019-04-17 | 2022-01-01 | 美商基利科學股份有限公司 | 類鐸受體調節劑之固體形式 |
| TW202210480A (zh) | 2019-04-17 | 2022-03-16 | 美商基利科學股份有限公司 | 類鐸受體調節劑之固體形式 |
| US11453681B2 (en) | 2019-05-23 | 2022-09-27 | Gilead Sciences, Inc. | Substituted eneoxindoles and uses thereof |
| CN114245807B (zh) | 2019-06-25 | 2025-05-02 | 吉利德科学公司 | Flt3l-fc融合蛋白和使用方法 |
| WO2021011891A1 (en) | 2019-07-18 | 2021-01-21 | Gilead Sciences, Inc. | Long-acting formulations of tenofovir alafenamide |
| US20220296619A1 (en) | 2019-08-19 | 2022-09-22 | Gilead Sciences, Inc. | Pharmaceutical formulations of tenofovir alafenamide |
| HRP20241379T1 (hr) | 2019-09-30 | 2024-12-20 | Gilead Sciences, Inc. | Cjepiva za hbv i postupci za liječenje hbv |
| US12410418B2 (en) | 2019-12-06 | 2025-09-09 | Precision Biosciences, Inc. | Optimized engineered meganucleases having specificity for a recognition sequence in the Hepatitis B virus genome |
| KR102987126B1 (ko) | 2020-03-20 | 2026-07-07 | 길리애드 사이언시즈, 인코포레이티드 | 4'-c-치환된-2-할로-2'-데옥시아데노신 뉴클레오시드의 프로드러그 및 이의 제조 및 사용 방법 |
| LT4192474T (lt) | 2020-08-07 | 2025-11-25 | Fosfonamidų nukleotidų analogų provaistai ir jų farmacinis panaudojimas | |
| TWI815194B (zh) | 2020-10-22 | 2023-09-11 | 美商基利科學股份有限公司 | 介白素2-Fc融合蛋白及使用方法 |
| US20240269142A1 (en) | 2021-05-13 | 2024-08-15 | Gilead Sciences, Inc. | COMBINATION OF A TLR8 MODULATING COMPOUND AND ANTI-HBV siRNA THERAPEUTICS |
| CN117355531A (zh) | 2021-06-23 | 2024-01-05 | 吉利德科学公司 | 二酰基甘油激酶调节化合物 |
| MX2023014762A (es) | 2021-06-23 | 2024-01-15 | Gilead Sciences Inc | Compuestos moduladores de diacilglicerol quinasa. |
| JP7651018B2 (ja) | 2021-06-23 | 2025-03-25 | ギリアード サイエンシーズ， インコーポレイテッド | ジアシルグリセロールキナーゼ調節化合物 |
| EP4359413A1 (en) | 2021-06-23 | 2024-05-01 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| WO2024111560A1 (ja) | 2022-11-21 | 2024-05-30 | 日本新薬株式会社 | Ｄｄｒ１キナーゼ阻害剤としての化合物および医薬 |
| WO2025240246A1 (en) | 2024-05-13 | 2025-11-20 | Gilead Sciences, Inc. | Combination therapies with ribavirin |
| US20250345390A1 (en) | 2024-05-13 | 2025-11-13 | Gilead Sciences, Inc. | Combination therapies |
| TW202608468A (zh) | 2024-05-13 | 2026-03-01 | 美商基利科學股份有限公司 | 組合療法 |
| WO2025240242A1 (en) | 2024-05-13 | 2025-11-20 | Gilead Sciences, Inc. | Combination therapies with ribavirin |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6593349B2 (en) | 2001-03-19 | 2003-07-15 | Icagen, Inc. | Bisarylamines as potassium channel openers |
| PL374946A1 (en) * | 2002-09-05 | 2005-11-14 | Aventis Pharma S.A. | Novel aminoindazole derivatives as medicines and pharmaceutical compositions containing same |
| US7442698B2 (en) * | 2003-07-24 | 2008-10-28 | Amgen Inc. | Substituted heterocyclic compounds and methods of use |
| FR2882361A1 (fr) * | 2005-02-22 | 2006-08-25 | Aventis Pharma Sa | Nouveaux derives de 3-aryl-1,2-benzisoxazole, compositions les contenant et leur utilisation |
| DE602007004638D1 (de) * | 2006-07-20 | 2010-03-18 | Amgen Inc | Benzoädüisoxazol-derivate als c-kit-tyrosinkinase-hemmer zur behandlung von erkrankungen im zusammenhang mit der überproduktion von histamin |
| EA018503B1 (ru) | 2007-07-20 | 2013-08-30 | НЕРВИАНО МЕДИКАЛ САЙЕНСИЗ С.р.л. | Замещенные производные индазола, активные как ингибиторы киназы |
| KR101361027B1 (ko) | 2008-11-28 | 2014-02-11 | 코와 가부시키가이샤 | 피리딘-3-카르복시아미드 유도체 |
| US8846935B2 (en) * | 2010-05-07 | 2014-09-30 | Glaxosmithkline Llc | Indazoles |
| WO2012118812A2 (en) * | 2011-02-28 | 2012-09-07 | Epizyme, Inc. | Substituted 6,5-fused bicyclic heteroaryl compounds |
| SI2934145T1 (en) | 2012-12-19 | 2018-03-30 | Celgene Quanticel Research, Inc. | Histone demethylase inhibitors |
-
2013
- 2013-12-19 SI SI201330913T patent/SI2934145T1/en unknown
- 2013-12-19 HU HUE13866465A patent/HUE037312T2/hu unknown
- 2013-12-19 DK DK13866465.1T patent/DK2934145T3/en active
- 2013-12-19 PT PT138664651T patent/PT2934145T/pt unknown
- 2013-12-19 ES ES13866465.1T patent/ES2658597T3/es active Active
- 2013-12-19 EP EP13866465.1A patent/EP2934145B1/en active Active
- 2013-12-19 JP JP2015549728A patent/JP6256772B2/ja not_active Expired - Fee Related
- 2013-12-19 US US14/653,818 patent/US9617242B2/en active Active
- 2013-12-19 LT LTEP13866465.1T patent/LT2934145T/lt unknown
- 2013-12-19 CA CA2895355A patent/CA2895355A1/en not_active Abandoned
- 2013-12-19 US US14/134,989 patent/US8969343B2/en active Active
- 2013-12-19 PL PL13866465T patent/PL2934145T3/pl unknown
- 2013-12-19 WO PCT/US2013/076666 patent/WO2014100463A1/en not_active Ceased
- 2013-12-19 SM SM20180070T patent/SMT201800070T1/it unknown
- 2013-12-19 RS RS20180071A patent/RS56821B1/sr unknown
- 2013-12-19 HR HRP20180067TT patent/HRP20180067T1/hr unknown
- 2013-12-19 AU AU2013361255A patent/AU2013361255B2/en not_active Ceased
-
2017
- 2017-03-01 US US15/446,996 patent/US10040779B2/en active Active
-
2018
- 2018-02-09 CY CY20181100164T patent/CY1119901T1/el unknown
- 2018-06-29 US US16/024,452 patent/US10336727B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| SMT201800070T1 (it) | 2018-03-08 |
| WO2014100463A1 (en) | 2014-06-26 |
| LT2934145T (lt) | 2018-02-26 |
| US10336727B2 (en) | 2019-07-02 |
| US20140171432A1 (en) | 2014-06-19 |
| US9617242B2 (en) | 2017-04-11 |
| EP2934145B1 (en) | 2017-11-15 |
| EP2934145A4 (en) | 2016-06-29 |
| HUE037312T2 (hu) | 2018-08-28 |
| US8969343B2 (en) | 2015-03-03 |
| PL2934145T3 (pl) | 2018-04-30 |
| ES2658597T3 (es) | 2018-03-12 |
| HRP20180067T1 (hr) | 2018-02-23 |
| US20160060247A1 (en) | 2016-03-03 |
| CA2895355A1 (en) | 2014-06-26 |
| AU2013361255A1 (en) | 2015-07-09 |
| EP2934145A1 (en) | 2015-10-28 |
| AU2013361255B2 (en) | 2017-01-05 |
| US20180305336A1 (en) | 2018-10-25 |
| SI2934145T1 (en) | 2018-03-30 |
| US10040779B2 (en) | 2018-08-07 |
| DK2934145T3 (en) | 2018-02-05 |
| JP2016503799A (ja) | 2016-02-08 |
| CY1119901T1 (el) | 2018-06-27 |
| PT2934145T (pt) | 2018-02-13 |
| RS56821B1 (sr) | 2018-04-30 |
| US20170174656A1 (en) | 2017-06-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10336727B2 (en) | Histone demethylase inhibitors | |
| US11987560B2 (en) | Inhibitors of lysine specific demethylase-1 | |
| JP6663866B2 (ja) | リジン特異的なデメチラーゼ−１の阻害剤 | |
| JP6256771B2 (ja) | ヒストンデメチラーゼ阻害剤 | |
| JP6276378B2 (ja) | ヒストンデメチラーゼ阻害剤 | |
| JP6320506B2 (ja) | ヒストンデメチラーゼ阻害剤 | |
| JP6525422B2 (ja) | リジン特異的なデメチラーゼ−１の阻害剤 | |
| JP6332654B2 (ja) | ヒストンデメチラーゼ阻害剤 | |
| CN106660987B (zh) | 赖氨酸特异性脱甲基酶-1的抑制剂 | |
| TW202124369A (zh) | 組織蛋白去甲基化酶抑制劑 | |
| JP2019508447A (ja) | ヒストンデメチラーゼ阻害剤 | |
| KR20170048601A (ko) | 히스톤 탈메틸효소 억제제 | |
| CN115551496A (zh) | Stat抑制性化合物和组合物 | |
| CN121729412A (zh) | 作为cdk抑制剂的双环化合物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20150721 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20161012 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20161019 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20170810 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20170821 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20171017 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20171101 |
|
| A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20171106 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20171122 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6256772 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| LAPS | Cancellation because of no payment of annual fees |